Kura Oncology, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.kuraoncology.com

Moat Score
Safety Score

Market Cap $471.34M
PE -3
Debt $9.57M
Cash $51.27M
EV $429.64M
FCF $110.55M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$181.89M
EBIT	-$179.64M
ROE	-50%
ROA	-24%
FCF	$110.55M
Equity	$364.41M
Growth Stability	1
PE	-2.59
PB	1.29
P/FCF	4.26
Price/Cash	0.11
Debt/Equity	0.03
Debt/FCF	0.09
Net Margins	-407%
Equity CAGR	31%
Earnings Growth YoY	16%
Earnings Growth QoQ	199%

Equity CAGR 5Y	-2%
Equity CAGR 3Y	-2%
Market Cap	$471.34M
Assets	$743.76M
Total Debt	$9.57M
Cash	$51.27M
Shares Outstanding	80.78M
EV	429.64M
Moat Score	1%
Safety Score	98%
Working Capital	634.43M
Current Ratio	8.07
Shares Growth 3y	8%
Equity Growth QoQ	-12%
Equity Growth YoY	-28%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.

SEC Filings

Direct access to Kura Oncology, Inc. (KURA) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Kura Oncology, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Kura Oncology, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Kura Oncology, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Kura Oncology, Inc..

Years

Calculation mode

= $1.1B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$111M	$111M	$111M	$111M	$111M	$111M	$111M	$111M	$111M	$111M	$111M	$1.1B
DCF		$101M	$91M	$83M	$76M	$69M	$62M	$57M	$52M	$47M	$43M	$426M
Value	$1.1B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-	-	-	-	-	-	-	-323%	-407%
ROA	-	-	-	-	-	-	-	-	-34%	-23%	-24%
ROE	-	-48%	-44%	-38%	-29%	-15%	-26%	-32%	-38%	-42%	-50%

Bad Net Margins (-407.07%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-0.08	-0.07	0.09	0.09
Debt over Equity	-	0.13	0.11	0.05	0.04	0.02	-	0.02	0.02	0.03	0.03
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (0.09)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (0.03)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	-	-	-	-	-
Earnings YoY growth	-	22%	29%	71%	4%	42%	46%	4%	12%	14%	-
Equity YoY growth	-	-31%	40%	102%	36%	179%	-17%	-17%	-5%	4%	-2%
FCF YoY growth	-	-	-	-	-	-	47%	5%	13%	-207%	-